Seattle Genetics & Astellas bag accelerated approval for PADCEV™
Category: #health  | By Mateen Dalal  | Date: 2019-12-20 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Seattle Genetics & Astellas bag accelerated approval for PADCEV™

Seattle Genetics, Inc., a biotechnology company based in U.S., and Astellas Pharma Inc. have recently revealed that the U.S. Food and Drug Administration (FDA) has given PADCEV™ an accelerated approval for treating adult patients with metastatic or locally advanced urothelial cancer. It would be given to patients that have gone through platinum-containing chemotherapy and a PD-1/L1 inhibitor in the past.

According to reliable sources, the remarkable tumor response rate of PADCEV has led to its approval under the FDA’s Accelerated Approval Program. Continued approval would still be subject to the drug’s description and verification of clinical benefit in confirmatory studies.

Apparnetly, PADCEV would be the first-ever treatment to be approved by the FDA in the U.S for advanced urothelial cancer patients . It is a novel ADC (antibody-drug conjugate) that is formulated against Nectin-4, a protein found on top of cells and is highly expressed in bladder cancer.

According to Roger Dansey, M.D., Chief Medical Officer, Seattle Genetics, PADCEV marks as the first approved ADC for patients suffering from urothelial cancer. This approval is a result of the innovative work that both the company has done on this technology.

Prior to this news, Seattle Genetics had made headlines when it bagged approval for ADCETRIS® in the supplemental New Drug Submission from Health Canada. As per the approval, ADCETRIS would be used in combination with CHP chemotherapy for the treatment of untreated PTCL (peripheral T-cell lymphoma)-NOS (not otherwise specified), angioimmunoblastic T-cell lymphoma (AITL) or sALCL (systemic anaplastic large cell lymphoma) in adult patients whose tumors express CD30.

Commenting on which, Dansey said that with this new indication for ADCETRIS, eligible patients and physicians in Canada can have access to this drug for treating frontline CD30-expressing PTCL, a key milestone supporting the firms vision to continue expanding ADCETRIS globally.

Source Credit: https://investor.seattlegenetics.com/press-releases/news-details/2019/FDA-Grants-Accelerated-Approval-to-Astellas-and-Seattle-Genetics-PADCEV-enfortumab-vedotin-ejfv-for-People-with-Locally-Advanced-or-Metastatic-Urothelial-Cancer-the-Most-Common-Type-of-Bladder-Cancer/default.aspx

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Oral-B & iADH partner to make oral care positive & accessible for all

Oral-B & iADH partner to make oral care positive & accessible for all

By Mateen Dalal

Oral-B, a well-known American oral hygiene products brand, has reportedly inked a partnership deal with iADH (International Association of Disability and Oral Health), in order to make oral care more positive, accessible, and inclusive for disabled p...

NEA AND SLA SIGN MOU TO SHARE GLOBAL NAVIGATION SATELLITE SYSTEM (GNSS)-DERIVED MOISTURE DATA FOR WEATHER MONITORING APPLICATION

NEA AND SLA SIGN MOU TO SHARE GLOBAL NAVIGATION SATELLITE SYSTEM (GNSS)-DERIVED MOISTURE DATA FOR WEATHER MONITORING APPLICATION

By Mateen Dalal

Singapore, 2 August 2022 – The National Environment Agency (NEA) and the Singapore Land Authority (SLA) have signed a Memorandum of Understanding (MOU) to develop the use of Global Navigation Satellite System (GNSS) data obtained from SLA&rsqu...

Baidu launches Apollo RT6; seeks expansion of its robotaxi fleet

Baidu launches Apollo RT6; seeks expansion of its robotaxi fleet

By Mateen Dalal

Baidu, a leading China-based artificial intelligence (AI) company and search engine, has reportedly uncovered its most recent electric autonomous driving vehicle. As per credible sources, the new vehicle, Apollo RT6, will be a part of the robotaxi...